Respicardia Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 81

Employees

  • Latest Deal Type
  • M&A

Respicardia General Information

Description

Developer of an implantable phrenic nerve stimulator technology designed to meet the needs in respiratory and cardiovascular disease with safe and effective therapies. The company's technology offers a transvenous implantable neurostimulation system that stimulates the phrenic nerve and improves respiratory rhythm management and cardiovascular health, enabling patients to restore natural breathing during sleep.

Contact Information

Website
www.respicardia.com
Formerly Known As
Cardiac Concepts, Cardiac Concepts Inc
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 12400 Whitewater Drive
  • Suite 150
  • Minnetonka, MN 55343
  • United States
Primary Industry
Therapeutic Devices
Acquirer
ZOLL Medical
Vertical(s)
Life Sciences
Corporate Office
  • 12400 Whitewater Drive
  • Suite 150
  • Minnetonka, MN 55343
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Respicardia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 09-Apr-2021 Completed Generating Revenue
8. Later Stage VC (Series D) 18-Dec-2017 Completed Generating Revenue
7. Later Stage VC (Series D) 28-Oct-2014 Completed Generating Revenue
6. Later Stage VC (Series D) 29-Aug-2013 Completed Generating Revenue
5. Debt - General 06-Aug-2012 Completed Generating Revenue
4. Later Stage VC (Series C) 11-Aug-2010 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2010 Completed Generating Revenue
2. Early Stage VC (Series B) 17-Oct-2008 $21M $26.7M Completed Generating Revenue
1. Early Stage VC (Series A) 08-Dec-2006 $5.64M $5.64M Completed Startup
To view Respicardia’s complete valuation and funding history, request access »

Respicardia Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series D
Series D1
Series C1
Series C
Series B 15,800,000 $0.010000 $0.11 $1.33 $1.33 1x $1.33 13.78%
Series A 4,903,973 $0.010000 $0.09 $1.15 $1.15 1x $1.15 4.28%
To view Respicardia’s complete cap table history, request access »

Respicardia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an implantable phrenic nerve stimulator technology designed to meet the needs in respiratory and cardiovasc
Therapeutic Devices
Minnetonka, MN
81 As of 2021

Arden Hills, MN
 

Mont-Saint-Guibert, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Respicardia Competitors (5)

One of Respicardia’s 5 competitors is Cryosa, a Venture Capital-Backed company based in Arden Hills, MN.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cryosa Venture Capital-Backed Arden Hills, MN
Nyxoah Formerly VC-backed Mont-Saint-Guibert, Belgium
Somnics Venture Capital-Backed Zhubei, Taiwan
Inspire Medical Systems Formerly VC-backed Golden Valley, MN
ResMed Corporation San Diego, CA
You’re viewing 5 of 5 competitors. Get the full list »

Respicardia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Respicardia Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Abbott Ventures Corporate Venture Capital Minority
Accuitive Medical Ventures Venture Capital Minority
Affinity Capital Management Venture Capital Minority
Ares Capital Lender/Debt Provider Minority
Asahi Kasei Corporate Venture Capital Corporate Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial

Respicardia FAQs

  • When was Respicardia founded?

    Respicardia was founded in 2006.

  • Where is Respicardia headquartered?

    Respicardia is headquartered in Minnetonka, MN.

  • What is the size of Respicardia?

    Respicardia has 81 total employees.

  • What industry is Respicardia in?

    Respicardia’s primary industry is Therapeutic Devices.

  • Is Respicardia a private or public company?

    Respicardia is a Private company.

  • What is Respicardia’s current revenue?

    The current revenue for Respicardia is .

  • How much funding has Respicardia raised over time?

    Respicardia has raised $153M.

  • Who are Respicardia’s investors?

    Abbott Ventures, Accuitive Medical Ventures, Affinity Capital Management, Ares Capital, and Asahi Kasei Corporate Venture Capital are 5 of 13 investors who have invested in Respicardia.

  • Who are Respicardia’s competitors?

    Cryosa, Nyxoah, Somnics, Inspire Medical Systems, and ResMed are competitors of Respicardia.

  • When was Respicardia acquired?

    Respicardia was acquired on 09-Apr-2021.

  • Who acquired Respicardia?

    Respicardia was acquired by ZOLL Medical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »